ScreenerHero

0RU5 Oncoinvent ASA

Partial data
LSE · GB · Healthcare · Biotechnology · oncoinvent.com
79.00NOK-6.51%Mkt Cap: —P/E: —

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap—
Enterprise Value19.73M USD
Revenue (TTM)2.62M USD
Gross Profit2.62M USD
Net Income (TTM)-14.50M USD
Revenue/Share22.65 NOK
Last Price79.00 NOK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees44
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-1.41
EV/Revenue7.52
P/S—
P/B2.70
EPS (TTM)-3.50
EPS (Forward)—
52W Range
79.000% of range88.38
52W High88.38 NOK
52W Low79.00 NOK
Profitability
Gross Margin100.00%
Oper. Margin-659.95%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-121.79%
ROA-52.64%
Growth
Revenue Growth100.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.14M USD
CapEx (TTM)—
FCF Margin-303.52%
FCF Yield—
Net Debt-16.27M USD
Net Debt/EBITDA1.16
Balance Sheet
Debt/Equity2.43
Current Ratio3.23
Quick Ratio3.20
Book Value/Sh32.67 NOK
Cash/Share39.66 NOK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 NOK
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.01:1
Split DateMay 30, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.54.71M
Float3.00M
Insiders23.07%
Institutions38.70%
Technical
SMA 500.2624 (+30005.1%)
SMA 2000.5130 (+15298.7%)
Beta—
S&P 52W Chg20.80%
Avg Vol (30d)623
Avg Vol (10d)133.58K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—